Literature DB >> 20008288

IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone.

Egídio Torrado1, Alexandra G Fraga, Elsa Logarinho, Teresa G Martins, Jenny A Carmona, José B Gama, Maria A Carvalho, Fernanda Proença, Antonio G Castro, Jorge Pedrosa.   

Abstract

Buruli ulcer, caused by Mycobacterium ulcerans infections, is a necrotizing skin disease whose pathogenesis is associated with the exotoxin mycolactone. Despite the relevance of this emergent disease, little is known on the immune response against the pathogen. Following the recent demonstration of an intramacrophage growth phase for M. ulcerans, we investigated the biological relevance of IFN-gamma and the antimycobacterial mechanisms activated by this cytokine in M. ulcerans-infected macrophages. Three M. ulcerans strains were tested: 5114 (mutant mycolactone-negative, avirulent strain); 94-1327 (intermediate virulence); and 98-912 (high virulence). We show in this study that IFN-gamma is expressed in mouse-infected tissues and that IFN-gamma-deficient mice display increased susceptibility to infection with strains 5114 and, to a lesser extent, 94-1327, but not with the highly virulent strain. Accordingly, IFN-gamma-activated cultured macrophages controlled the proliferation of the avirulent and the intermediate virulent strains. Addition of mycolactone purified from strain 98-912 to cultures of IFN-gamma-activated macrophages infected with the mycolactone-negative strain led to a dose-dependent inhibition of the IFN-gamma-induced protective mechanisms, involving phagosome maturation/acidification and increased NO production, therefore resulting in increased bacterial burdens. Our findings suggest that the protection mediated by IFN-gamma in M. ulcerans-infected macrophages is impaired by the local buildup of mycolactone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008288     DOI: 10.4049/jimmunol.0902717

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 2.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

3.  Serum levels of neopterin during antimicrobial treatment for Mycobacterium ulcerans infection.

Authors:  Janine de Zeeuw; Sridevi Duggirala; Willemien A Nienhuis; K Mohammed Abass; Wilson Tuah; Till F Omansen; Tjip S van der Werf; Ymkje Stienstra
Journal:  Am J Trop Med Hyg       Date:  2013-07-08       Impact factor: 2.345

4.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

5.  Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis.

Authors:  Andrea Cruz; Alexandra G Fraga; Jeffrey J Fountain; Javier Rangel-Moreno; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Troy D Randall; Jorge Pedrosa; Andrea M Cooper; António G Castro
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 14.307

6.  Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.

Authors:  Teresa G Martins; José B Gama; Alexandra G Fraga; Margarida Saraiva; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

7.  Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Authors:  Alexandra G Fraga; Teresa G Martins; Egídio Torrado; Kris Huygen; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

8.  Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.

Authors:  Teresa G Martins; Gabriela Trigo; Alexandra G Fraga; José B Gama; Adhemar Longatto-Filho; Margarida Saraiva; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS Negl Trop Dis       Date:  2012-11-29

9.  Structure-activity relationship studies on the macrolide exotoxin mycolactone of Mycobacterium ulcerans.

Authors:  Nicole Scherr; Philipp Gersbach; Jean-Pierre Dangy; Claudio Bomio; Jun Li; Karl-Heinz Altmann; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2013-03-28

10.  Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model.

Authors:  Gabriela Trigo; Teresa G Martins; Alexandra G Fraga; Adhemar Longatto-Filho; António G Castro; Joana Azeredo; Jorge Pedrosa
Journal:  PLoS Negl Trop Dis       Date:  2013-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.